- Home
- RLAY vs LANC Comparison
RLAY vs LANC Comparison
Compare RLAY & LANC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- LANC
- Stock Information
- Founded
- RLAY 2015
- LANC 1961
- Country
- RLAY United States
- LANC United States
- Employees
- RLAY N/A
- LANC N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- LANC Packaged Foods
- Sector
- RLAY Health Care
- LANC Consumer Staples
- Exchange
- RLAY Nasdaq
- LANC Nasdaq
- Market Cap
- RLAY 576.1M
- LANC N/A
- IPO Year
- RLAY 2020
- LANC N/A
- Fundamental
- Price
- RLAY $3.63
- LANC $181.57
- Analyst Decision
- RLAY Strong Buy
- LANC Buy
- Analyst Count
- RLAY 11
- LANC 4
- Target Price
- RLAY $18.40
- LANC $209.67
- AVG Volume (30 Days)
- RLAY 1.6M
- LANC 166.2K
- Earning Date
- RLAY 08-05-2025
- LANC 08-21-2025
- Dividend Yield
- RLAY N/A
- LANC 2.20%
- EPS Growth
- RLAY N/A
- LANC 27.36
- EPS
- RLAY N/A
- LANC 6.15
- Revenue
- RLAY $7,679,000.00
- LANC $1,886,520,000.00
- Revenue This Year
- RLAY $14.31
- LANC $3.16
- Revenue Next Year
- RLAY N/A
- LANC $2.33
- P/E Ratio
- RLAY N/A
- LANC $28.11
- Revenue Growth
- RLAY N/A
- LANC 0.69
- 52 Week Low
- RLAY $1.78
- LANC $156.14
- 52 Week High
- RLAY $10.72
- LANC $202.63
- Technical
- Relative Strength Index (RSI)
- RLAY 63.22
- LANC 69.91
- Support Level
- RLAY $3.10
- LANC $165.16
- Resistance Level
- RLAY $3.75
- LANC $173.11
- Average True Range (ATR)
- RLAY 0.23
- LANC 4.32
- MACD
- RLAY 0.03
- LANC 1.38
- Stochastic Oscillator
- RLAY 84.42
- LANC 85.49
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).